Karyopharm Therapeutics Inc.
KPTI · NASDAQ
Market closed$9.51$0.130000 (+1.39%)After hours $8.69 · -8.64%
Key statistics
Previous close$9.38
Open$9.41
Day high$9.58
Day low$9.37
52-week high$10.99
52-week low$3.65
Market cap215.52M
Volume184.66K
Average volume453.05K
P/E ratio-0.82
Forward P/E—
EPS-11.61
Dividend yield0.00%
Market context
Why it moved
Karyopharm Therapeutics shares edged higher as investor sentiment was supported by the company's announcement of a new 2026 Leadership Cash Retention Program for key executives, signaling confidence in upcoming meaningful catalysts ahead of its Q2 2026 earnings report.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · July 17, 2026Karyopharm Therapeutics (NASDAQ: KPTI) grants 2026 cash retention awards to key executivesMoomoo · July 9, 2026RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $16PR Newswire · May 14, 2026Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial EnrollmentKaryopharm · March 24, 2026Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume ReductionClinical Trials Arena · March 24, 2026Karyopharm’s Phase III myelofibrosis trial delivers mixed resultsInvesting.com · March 24, 2026Karyopharm’s myelofibrosis trial meets one of two primary goalsKaryopharm · February 12, 2026Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company ProgressKaryopharm · November 3, 2025Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress Mt Newswire · June 2, 2026Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Benzinga · June 2, 2026Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted For Late-Breaking Oral Presentation At EHA 2026 Benzinga · June 2, 2026Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentation Titled: Selinexor Plus Ruxolitinib In JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial At 2026 ASCO Annual Meeting Benzinga · May 14, 2026Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript Benzinga · May 14, 2026Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $137.489M Est Benzinga · May 14, 2026Karyopharm Therapeutics Q1 EPS $(1.24) Beats $(1.40) Estimate, Sales $35.066M Beat $31.399M Estimate Benzinga · May 4, 2026Karyopharm Therapeutics Files Prospectus For Offering $400M Mixed Shelf Benzinga · April 21, 2026Karyopharm Therapeutics Phase 3 SENTRY Trial In Myelofibrosis Accepted For Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting